全球大型製药企业的联盟条件与契约 (2020～2024年)

本报告提供了有关公司为何以及在什么条件下与主要製药公司进行合作的详细资讯和分析。这些协议往往是多方面的，从联合研发开始，一直到成果的商业化。

本报告提供了自 2020 年以来生命科学领域宣布的 2,022 项主要製药公司协议的详细资讯。

本报告全面回顾了主要製药公司之间的合约趋势、主要公司、主要合约金额和合约财务，并研究了各公司如何、为何以及在什么条件下与主要製药公司签订了合作协议，您可以了解什么。

本报告从财务角度评估主要製药公司的交易期限和价值，并提供交易总额、预付款、里程碑和特许权使用费等信息，帮助读者了解交易的财务价值。

本报告的中间部分研究了大型製药公司的合作伙伴和主要交易者。报告了大型製药公司中关键交易的交易价值和最活跃的交易撮合者，让读者了解哪些公司在这个充满活力的交易市场中取得了成功。

交易各方揭露的主要药企网上交易记录，包含在以下目录格式：

• 公司名称（A-Z）
• 发展阶段
• 交易类型
• 治疗重点领域
• 技术类型
• 此外，我们也会记录公司及其关联公司向美国证券交易委员会提交的合约文件（如果有）。虽然许多公司希望了解其付款条件的详细信息，但在付款方式方面，细节才是王道。
• 本报告也包含一些图表，显示 2020 年以来大型製药公司的联盟和交易趋势和活动。
• 总而言之，本报告提供了潜在交易者需要了解的有关主要製药公司研发和商业化合作伙伴关係的所有资讯。

主要优点

该报告为读者提供了以下主要好处：

• 主要製药公司合约趋势的详细资料（2020年起）
• 取得交易金额、预付款、里程碑和版税率数据
• 主要製药公司与主要生物製药公司签署的实际协议：查看详细信息
• 确定大型製药公司最活跃的交易撮合者（2020 年及以后）
• 公司过去同意的主要合约条件的说明
• 进行尽职调查：评估向合作伙伴公司提出的合约条款的适当性

调查范围

• 本报告旨在让读者深入了解和了解全球领先公司与大型製药公司达成的交易的趋势和结构。

主要製药公司的合作条件和合约细节：

• 生医产业主要药厂交易趋势（2020年后）
• 取得交易金额、预付款、里程碑和版税率数据
• 取得主要製药公司的合约文件
• 与主要製药公司的交易金额（2020年起）
• 大型製药公司中最活跃的交易撮合者（2020 年起）

此报告列出了可用合约的以下资讯：

• 公司名称（A-Z）
• 总交易金额
• 合约签订时的开发阶段
• 合约组成部分的类型
• 具体治疗标靶
• 技术类型
• 每笔交易的标题都透过网路连结连结到交易记录的线上版本以及合约文件（如果有），从而可以轻鬆按需存取每份合约文件。
• 此报告提供对大型製药公司可用交易和合约文件的全面存取。

透过分析实际合同，可以评估：

• 授予或选择的具体权利是什么？
• 合约实际上赋予了合作伙伴公司什么？
• 授予哪些类型的专有权？
• 合约的付款结构是怎样的？
• 如何审核销售和付款？
• 合约期限是多久？
• 合约的主要条款是如何定义的？
• 智慧财产权的处理和所有权如何？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已就何种类型的分授权或分包条款达成协议？
• 公司主张哪些样板条款？
• 根据合作伙伴关係或交易的类型，哪些样板条款看起来有所不同？
• 公司对契约法主张哪一个管辖权？

目录

执行摘要

第一章简介

第二章主要药企交易走势

• 简介
• 主要製药公司之间的长期联盟趋势
• 主要製药公司最活跃的交易撮合者
• 主要製药公司之间的合作趋势：按交易类型划分
• 主要製药公司之间的联盟趋势：按治疗领域
• 主要製药公司之间的合作趋势：依技术类型划分
• 与各大药厂合作的条件
  • 与主要製药公司联盟的交易总额
  • 主要製药公司交易的预付款
  • 主要製药公司交易的里程碑付款
  • 主要药厂的专利费率

第三章主要医药企业重大交易

• 简介
• 主要製药公司的主要交易：交易金额

第 4 章主要药厂最活跃的交易撮合者

• 简介
• 大药厂最活跃的交易撮合者
• 大药厂最活跃的合作伙伴：简介

第五章主要药厂合约交易一览

• 简介
• 主要药厂合约交易列表

第六章主要製药公司交易趋势：依技术类型划分

附录

Global Big Pharma Partnering Terms and Agreements 2020 to 2024 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of 2,022 Big Pharma agreements announced in the life sciences since 2020.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Online deal records of Big Pharma deals as disclosed by the deal parties are included in a directory format by:

• Company A-Z
• Stage of development
• Deal type
• Therapy focus
• Technology type
• In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
• The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2020, including details of headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Big Pharma deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.
• Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2020, where a contract document is available in the public domain. Each deal title links via hyperlink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2020. The chapter is organized by specific technology type. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
• A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
• The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2020.
• In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

Global Big Pharma Partnering Terms and Agreements 2020-2024 provides the reader with the following key benefits:

• In-depth understanding of Big Pharma deal trends since 2020
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
• Identify most active Big Pharma dealmakers since 2020
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Big Pharma Partnering Terms and Agreements 2020-2024 is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

Big Pharma Partnering Terms and Agreements includes:

• Trends in Big Pharma dealmaking in the biopharma industry since 2020
• Access to headline, upfront, milestone and royalty data
• Access to Big Pharma contract documents
• Leading Big Pharma deals by value since 2020
• Most active Big Pharma dealmakers since 2020

In Global Big Pharma Partnering Terms and Agreements 2020-2024, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• The Global Big Pharma Partnering Terms and Agreements 2020-2024 report provides comprehensive access to available Big Pharma deals and contract documents.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

• 2.1. Introduction
• 2.2. Big Pharma partnering over the years
• 2.3. Most active Big Pharma dealmakers
• 2.4. Big Pharma partnering by deal type
• 2.5. Big Pharma partnering by therapy area
• 2.6. Big Pharma partnering by technology type
• 2.7. Deal terms for Big Pharma partnering
  • 2.7.1 Big Pharma partnering headline values
  • 2.7.2 Big Pharma deal upfront payments
  • 2.7.3 Big Pharma deal milestone payments
  • 2.7.4 Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

• 3.1. Introduction
• 3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

• 4.1. Introduction
• 4.2. Most active Big Pharma dealmakers
• 4.3. Most active Big Pharma partnering company profiles

Chapter 5 - Big Pharma contracts dealmaking directory

• 5.1. Introduction
• 5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Appendices

• Appendix 1 - Big Pharma deals by company A-Z
• Appendix 2 - Big Pharma deals by stage of development
• Appendix 3 - Big Pharma deals by deal type
• Appendix 4 - Big Pharma deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Big Pharma partnering since 2020
• Figure 2: Active Big Pharma dealmaking activity 2020-2024
• Figure 3: Big Pharma partnering by deal type since 2020
• Figure 4: Big Pharma partnering by disease type since 2020
• Figure 5: Big Pharma partnering by technology type since 2020
• Figure 6: Big Pharma deals with a headline value
• Figure 7: Big Pharma deals with an upfront value
• Figure 8: Big Pharma deals with a milestone value
• Figure 9: Big Pharma deals with a royalty rate value
• Figure 10: Top Big Pharma deals by value since 2020
• Figure 11: Most active Big Pharma dealmakers 2020-2024